1

Elanco

#2432

Rank

$5.86B

Marketcap

US United States

Country

Elanco
Leadership team

Mr. Jeffrey N. Simmons (Pres, CEO & Director)

Mr. Todd S. Young (Exec. VP of Corp. Governance and Strategy & CFO)

Mr. Ramiro Martin Cabral (Exec. VP & Pres of Elanco International)

Products/ Services
Biotechnology, Health Care, Pet, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Greenfield, Indiana, United States
Established
1954
Company Registration
SEC CIK number: 0001739104
Revenue
Above - 1B
Traded as
ELAN
Social Media
Overview
Location
Summary
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
History

The company can trace its roots back to 1953 when Eli Lilly introduced their first antibiotic aimed at veterinary usage with the new plant and animal sciences research being combined into Lilly's Agro-Industrial division led by George Barnes. In the 1960s, the Agro-Industrial division was reorganised launching Elanco Products, short for the parent company name, Eli Lilly and Company.The 1970s marked a decade of expansion for the business, increasing international operations to 38 global affiliates and 17 manufacturing locations. In the 1980s research moved away from plant sciences and focused on animal health and food quality. In the 1990s another reorganisation led to the company being renamed Elanco Animal Health, focusing solely on animal health.In 2007 the business acquired Ivy Animal Health and launched its companion animal business. In 2008 Elanco partnered with Heifer International in order to address food security in developing nations. In 2009 the business launched its data analytics business, Elanco Knowledge Solutions.In 2010 the business acquired the European rights to a portfolio of Pfizer Animal Health treatments and an Irish manufacturing site. In 2011, Elanco expanded its footprint in Europe, acquiring Janssen Animal Health and committed to ending hunger for 100,000 families through the Heifer International partnership. In 2012 the business acquired ChemGen Corp., improving their offering in enzyme-based nutrient absorption tools for food-livestock. In 2014, the business acquired Lohmann SE and Lohmann Animal Health for an undisclosed sum and Novartis Animal Health for $5.4 billion, the former boosting Elanco's poultry and vaccine business and the latter increasing a broad spectrum of treatments across companion animal, livestock, vaccine and aquaculture offerings. In 2016 Elanco expanded its US-based business, acquiring a suite of vaccines from Boehringer Ingelheim Vetmedica for $885 million.In 2018, Lilly announced plans to separate its Elanco Animal Health unit from the rest of the business via an initial public offering on the New York Stock Exchange, with the stock-ticker ELAN. In 2019, the divestiture was completed and Elanco launched on the New York Stock Exchange. In the same year, the US FDA approved rabacfosadine, a first-in-class treatment for canine lymphoma. The business continued to expand is US-business, acquiring Aratana Therapeutics, and its first-in-class treatment for canine osteoarthritis. Elanco also announced it would acquire the developer of vaccines for bacterial disease prevention in food-animals, Prevtec Microbia, Inc. In the same year the business announced it would acquire Bayer's animal health business for $7.6 billion.On December 3, 2020, Elanco announced plans to build a new global headquarters in Indianapolis at the site of the former GM stamping plant, which is located across the White River from the downtown area. The business plans to break ground on the new headquarters in the first half of 2021.In August 2021, Elanco announced it had closed its acquisition of Kindred Biosciences, enhancing its existing biologics and monoclonal antibody pipeline.Elanco's flea and tick collar, branded "Seresto" and manufactured by Bayer Animal Health which was acquired by Elanco in 2020, has been linked to more than 98,000 incidents of poisoning by pesticide, including more than 2,000 pet deaths, according to a 2022 report by a subcommittee of the House Committee on Oversight and Reform. The collars have been banned in Canada.

Mission
We provide those who raise and care for animals with a comprehensive set of animal health products and knowledge services that empower them to address the global challenges of a diverse and changing world.
Vision
Elanco’s vision is to be the global leader in food animal health and wellbeing.
Key Team

Mr. James M. Meer (Sr. VP & Chief Accounting Officer)

Mr. Chris Keeley (Sr. VP & Chief Information Officer)

Mr. David S. Kinard (Exec. VP of HR Corp. Affairs & Admin.)

Ms. Marcela A. Kirberger (Exec. VP, Gen. Counsel & Corp. Sec.)

Mr. David Alan Urbanek (Exec. VP of Manufacturing & Quality)

Mr. Shawn McKee (Sr. VP of U.S. Companion Animal)

Mr. Larbi Van Lier (Sr. VP of Asia)

Recognition and Awards
Elanco has won multiple awards globally for its dedication to providing quality animal health products, including the US Animal Health Association’s Special Recognition Award ; Agri Corner magazine’s Animal Health Company of the Year ; and CPhI Pharma Awards India’s Animal Health Industry Award .
References
Elanco
Leadership team

Mr. Jeffrey N. Simmons (Pres, CEO & Director)

Mr. Todd S. Young (Exec. VP of Corp. Governance and Strategy & CFO)

Mr. Ramiro Martin Cabral (Exec. VP & Pres of Elanco International)

Products/ Services
Biotechnology, Health Care, Pet, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Greenfield, Indiana, United States
Established
1954
Company Registration
SEC CIK number: 0001739104
Revenue
Above - 1B
Traded as
ELAN
Social Media